TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Study to Evaluate ISV-305 Compared to Vehicle in Blepharitis Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Are at least 1 years of age and have a clinical diagnosis of active, symptomatic blepharitis~* Signature of the subject or parent(s) or legally authorized representative on the Informed Consent Form, and when appropriate the minor's assent in accordance with local regulations~* Are willing and able to follow all instructions and attend all study visits (this applies to parent or caregiver for subjects too young to self-apply investigational product)~* Are willing to avoid disallowed medication for the duration of the study~* If female is of childbearing potential, agree to and submit a urine sample for pregnancy testing (prior to enrollment and at the end of the study) and use effective contraception for the duration of the study~* Male subjects whose female partners are not post-menopausal must agree to one of the following: 1) completely abstain from sexual intercourse, 2) use a barrier method (condoms) with spermicide during sexual intercourse for the duration of the study, 3) provide documentation for having had a vasectomy (with documented infertility)~* Additional inclusion criteria also apply~Exclusion Criteria:~* Have known sensitivity or poor tolerance to any component of the study drugs~* Have had eyelid surgery in the study eye within twelve (12) months prior to Visit 1 or plan to have eyelid surgery during the study~* Have an acute ocular infection (bacterial, viral or fungal) or active ocular inflammation other than blepharitis in the study eye~* Have used topical medications on the eyelids or topical ophthalmic corticosteroid medications or systemic use of a corticosteroid mediation within 14 days prior to dosing and/or plan to use them throughout the duration of the study~* Be currently pregnant, nursing, or planning a pregnancy; or be a woman who has a positive urine pregnancy test~* Have prior (within 30 days prior to dosing) or anticipated concurrent use of an investigational drug or device~* Have a condition or a situation which, in the investigator's opinion, may put the subject at increased risk, confound study data, or interfere significantly with the subject's study participation~* Additional exclusion criteria also apply

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ISV-305 (Type: EXPERIMENTAL): 0.1% dexamethasone in DuraSite® 2
- Vehicle (Type: PLACEBO_COMPARATOR): DuraSite® 2 vehicle

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mass-balance Study of [14C]-APD421 in Healthy Volunteers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy males~* Age 18 to 65 years of age at time of signing informed consent~* Body mass index (BMI) of 18 to 30 kg/m2 or, if outside the range, considered not clinically significant by the investigator~* Must be willing and able to communicate and participate in the whole study~* Must provide written informed consent~* Must agree to use an adequate method of contraception (as defined in Section 8.4)~* Must have regular bowel movements (ie average stool production of ≥1 and ≤3 stools per day)~Exclusion Criteria:~* Prior participation in another study with a radiation burden of \> 0.1 mSv and ≤ 1 mSv in the period of 1 year prior to screening; a radiation burden of \> 1 mSv and ≤ 2 mSv in the period of 2 years prior to screening; a radiation burden of \> 2 mSv and ≤ 3 mSv in the period of 3 years prior to screening, etc (add 1 year per 1 mSv)

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- 14C-APD421 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Pneumococcal Vaccine in Healthy Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Aged 6 weeks to 14 weeks (42-98 days of age) at time of enrollment,~2. In good health as determined by medical history, physical examination and judgment of the investigator,~3. Subject must have been born ≥36 weeks of gestational age,~4. Subject must be available for entire study period and whose parent/legal guardian can be reached by telephone,~5. Parent/legal guardian must be able to understand and sign an informed consent form prior to participation and complete a parent worksheet during study participation.~Exclusion Criteria:~1. Previous vaccination with licensed or investigational pneumococcal vaccine,~2. Previous vaccination with Hib conjugate, DTaP or IPV vaccines,~3. Contraindication to immunization with HepB, Hib conjugate, DTaP or IPV vaccines,~4. Significant neurological disorder or history of seizure including febrile seizure, or significant stable or evolving disorders such as cerebral palsy, encephalopathy, hydrocephalus or other significant disorders. Does not include resolving syndromes due to birth trauma such as Erb palsy,~5. Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection,~6. History of culture-proven invasive disease caused by S. pneumoniae,~7. Previous anaphylactic reaction to any vaccine or vaccine components,~8. Major known congenital malformation or serious chronic disorders,~9. Participation in another investigational study (however, observation-only trials are permitted),~10. Known or suspected immune deficiency/suppression,~11. Receipt of blood products or gamma globulin (including Hepatitis B immunoglobulin and monoclonal antibody; eg, Synagis®).

- Gender: ALL
- Minimum Age: 42 Days
- Maximum Age: 98 Days
- Healthy Volunteers: t

Study Arms:
- 13vPnC (Type: EXPERIMENTAL): None
- 7vPnC (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Stargardt Macular Dystrophy Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Must have been treated with hESC-RPE cell transplant in the core protocol.~* Able to understand and willing to sign the informed consent to participate in the follow-up study.~Exclusion Criteria:~* There are no exclusion criteria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental: MA09-hRPE (Type: None): Sub-retinal transplantation of MA09-hRPE cells

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SMART-DAPPER: Leveraging the Depression And Primary-care Partnership for Effectiveness-implementation Research Project

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. Kisumu County Hospital (KCH) adult primary care outpatient clinic attendees who screen positive for depression and/or PTSD~2. Ability to attend weekly IPT sessions/fluoxetine monitoring; (3) 18 years or older~Exclusion Criteria:~1. Cognitive dysfunction compromising ability to participate in IPT or accurately take fluoxetine (lack of orientation to person, place, time and situation)~2. acute suicidality requiring higher level of care~3. drug/alcohol use disorders requiring substance use treatment (AUDIT score of 8 or higher, DAST score of 3 or higher)~4. history of mania or requiring treatment for hypomania~5. Outside mental health treatment during the study treatment phases (any mental health treatment is allowed during follow-up phases and is recorded by study team).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Interpersonal psychotherapy (Type: ACTIVE_COMPARATOR): IPT was developed in the 1980s by Gerald Klerman and Myrna Weissman to address interpersonal issues in depression. IPT is now considered evidence-based, first-line treatment for depression. IPT improves symptoms by addressing problems in social relationships. IPT is traditionally delivered as weekly one-hour sessions over 12 weeks, focused on one interpersonal problem area.
- fluoxetine (Type: ACTIVE_COMPARATOR): Fluoxetine is a selective serotonin reuptake inhibitor that is FDA approved for the treatment of depression. Compared to placebo, fluoxetine is more likely to produce symptom response for MDD. Despite the interim development of many other antidepressants since the development of fluoxetine, it remains a first line treatment for depression.
- Fluoxetine after IPT (Type: ACTIVE_COMPARATOR): participants who do not remit from MDD and PTSD after treatment with IPT may be randomized to fluoxetine.
- IPT after fluoxetine (Type: ACTIVE_COMPARATOR): participants who do not remit from MDD and PTSD after treatment with fluoxetine may be randomized to IPT.
- IPT + fluoxetine (Type: ACTIVE_COMPARATOR): participants who do not remit from MDD and PTSD after treatment with fluoxetine may be randomized to IPT + fluoxetine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bispectral Index-Guided Versus Fixed Dose Administration of Desflurane During Balanced Anesthesia With Remifentanil

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients scheduled for operation under balanced anesthesia using desflurane and remifentanil~Exclusion Criteria:~* Refusal of consent~* General anesthesia with agents other than desflurane and remifentanil~* Patients with allergy to neuromuscular blocker, volatile anesthetics, opioids~* History of malignant hyperthermia~* Patients taking CNS stimulants~* Chronic alcohol abuser~* Patients with severe depressed left ventricular function, EF \< 30%~* Patients with convulsive disorders~* ASA class IV, V, VI~* Patients with systolic arterial blood pressure lower than 90mmHg before surgery~* Patients needing inotropic infusion during surgery~* Anesthesia time less than 30 minutes

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Administering desflurane according to the patient's BIS value (Type: EXPERIMENTAL): The anesthesiologist administers the volatile anesthetic desflurane to set the patient's BIS value at 50 during balanced anesthesia, and titrate the remifentanil dose to set the patient's systolic arterial blood pressure between 100-140mmHg.
- Administering desflurane at 1 MAC (Type: EXPERIMENTAL): The anesthesiologist administers the volatile anesthetic desflurane at 1 MAC during balanced anesthesia, and titrate the remifentanil dose to set the patient's systolic arterial blood pressure between 100-140mmHg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Difluprednate vs. Prednisolone Acetate on Visual Acuity, and Corneal Edema Following Cataract Surgery.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male or female 21 years of age or older~* Scheduled to undergo standard cataract surgery with topical anesthesia in both eyes within 6-25 days between surgeries.~* Willing and able to administer eye drops and record the times the drops were instilled~* Understand and are willing to sign the Informed Consent form~* Willing to complete the entire course of the study.~Exclusion Criteria:~* Use of an eye medication or drops within 48 hours of the scheduled cataract surgery, other than the study medication or procedural solution required for surgery.~* Known sensitivity to any of the ingredients in the study medications or similar medications.~* Scheduled for 2nd eye cataract surgery earlier than 6 days or longer than 25 days apart.~* Corneal edema in either eye.~* Need for regional or general anesthesia during surgery.~* Complicated cataract surgery, including use of iris hooks or iris stretchers.~* Sight better than 20/100 in only one eye.~* A history of previous intraocular surgery in either eye.~* A history of uveitis, iritis, or intraocular inflammation.~* Macular pathology of the retina.~* Presence of glaucoma.~* Any confirmed or suspected active viral, bacterial, or fungal keratoconjunctival disease.~* History of steroid-related intraocular pressure (IOP) rise in the study eye.~* Lack of an intact corneal epithelium.~* Pupils that do not dilate to more than 5 mm prior to surgery or you require mechanical stretching of your pupil.~* Diabetes mellitus.~* Required use of a systemic steroidal or non-steroidal anti-inflammatory during the study period.~* Doctor has determined the presence of a condition (i.e., UNCONTROLLED systemic disease) or a situation that may put the subject at significant risk, confound the study results or may interfere significantly with your participation in the study.~* Females, who are pregnant, nursing an infant or planning a pregnancy.~* Currently involved in another investigational study or have participated in one within the 30 days prior to entering this study.~* Unable or unwilling to give signed informed consent prior to participation in any study-related procedures.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Difluprednate Ophthalmic Emulsion 0.05% (Type: ACTIVE_COMPARATOR): None
- Prednisolone acetate suspension 0.1% (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Subsartorial Saphenous Block on Postoperative Pain Following Major Ankle and Hind Foot Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Elective ankle or hind foot surgery either: (1) total ankle arthroplasty, (2) ankle arthrodesis (3) subtalar arthrodesis or (4) triple arthrodesis~* Age ≥ 18~* American Society of Anaesthesiology Classification I-III~* Informed consent both orally and in writing after the patient has fully understood the protocol and its limitations.~Exclusion Criteria:~* Communication problems or dementia~* Allergies to any medical product used in the study~* Neuropathy of the sciatic or femoral nerve prior to the operation~* Morbus Charcot-Marie-Tooth disease, diabetic neuropathy, peripheral vascular disease~* Daily use of opioids~* Coagulation disorders~* Infection at the site of injection or systemic infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Bupivacaine-epinephrine (Type: EXPERIMENTAL): 10 mL of 5 mg/mL bupivacaine with 5 μg/mL epinephrine = 50 mg bupivacaine and 50 μg epinephrine
- Placebo (Type: PLACEBO_COMPARATOR): 10 ml normal saline water (sodium chloride solution, 0,9%)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Assessing Choice in the Employer Setting (ACES) Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria for employer sites:~* Located in the United States~* Has not previously offered FluMist in an employee vaccination program in the past or FluMist represented less than 5% of all vaccine received at past programs~* Data are available that will allow for a reliable estimate of the employee (total and 18-49 year old populations) vaccination rate for the 2007-2008 influenza season

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Arm A (Control) (Type: None): A control arm of usual care offering TIV with baseline advertisement
- Arm B (Choice) (Type: None): An intervention arm offering choice of TIV or FluMist with baseline advertisement, including advertisement to highlight the availability of FluMist
- Arm C (Choice Plus) (Type: None): An intervention arm offering choice of TIV or FluMist with enhanced advertisement and additional incentives for receiving an influenza vaccination

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Assessment in Work Productivity and the Relationship With Cognitive Symptoms in Patients With MDD Taking Vortioxetine

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The patient is a man or woman, aged ≥18 years and \<65 years (In the province of British Columbia, the patient must be aged 19 years or older in order to give Informed Consent)~* The patient is engaged in volunteer work or gainful employment (working ≥20 hours per week) or is enrolled full-time in post-secondary studies or vocational training.~* The patient is an outpatient consulting a Primary Care Physician or a Psychiatrist.~* Patients must have a diagnosis of MDD according to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5™) classification code 296.3x.~* The current MDE is confirmed by the investigator.~* The reported duration of the current MDE is at least 3 months.~* The patient has a Baseline score ≥15 on the QIDS-SR.~* The patient reports at least a minimal level of cognitive symptoms as defined by Baseline score of ≥30 on the PDQ-D-20.~* The patient is capable of communicating with the site personnel and is able to conduct the digit-symbol substitution test (DSST).~Exclusion Criteria:~* The patient score is \>69 on the DSST at Screening/Baseline.~* The patient is, in the opinion of the investigator, not able to complete all the study assessments including, but not limited to, patient-reported assessments and the DSST.~* The patient has a current diagnosis or history of manic or hypomanic episode, schizophrenia or any other psychotic disorder, including major depression with psychotic features.~* The current depressive symptoms are considered by the investigator to have been resistant to 2 adequate antidepressant treatments of at least 6 weeks duration each at the maximum recommended dose (according to Canadian labeling).~Other protocol defined inclusion and exclusion criteria do apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- vortioxetine naive (Type: OTHER): vortioxetine 10 mg 100 patients with Major Depressive Disorder who have not been treated with another antidepressant for the current MDE
- Switch (Type: OTHER): vortioxetine 10 mg 100 patients with Major Depressive Disorder that require a switch from their current antidepressant due to inadequate response

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: CONVERGE - Epi/Endo Ablation For Treatment of Persistent Atrial Fibrillation(AF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years; \< 80 years~* Left atrium \< 6.0 cm~* Refractory or intolerant to one AAD (class I and/or III)~* Documentation of persistent AF~* Provided written informed consent~Exclusion Criteria:~* Patients requiring concomitant surgery~* Left ventricular ejection fraction \< 40%~* Pregnant or planning to become pregnant during study~* Co-morbid medical conditions that limit one year life expectancy~* Previous cardiac surgery~* History of pericarditis~* Previous cerebrovascular accident (CVA), excluding fully resolved transient Ischemic attack (TIA)~* Patients who have active infection or sepsis~* Patients with esophageal ulcers strictures and varices~* Patients with renal dysfunction who are not on dialysis~* Patients who are contraindicated for anticoagulants~* Patients who are being treated for ventricular arrhythmias~* Patients who have had a previous left atrial catheter ablation for AF~* Patients with existing Implantable Cardioverter-Defibrillator (ICDs)~* Current participation in another clinical investigation of a medical device or a drug, or recent participation in such a study within 30 days prior to study enrollment~* Not competent to legally represent him or herself

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Convergent Procedure (Type: EXPERIMENTAL): Procedure/Surgery: Convergent Procedure using EPi-Sense-AF Guided Coagulation System with Endocardial Catheter Ablation Treatment
- Standalone Endocardial Catheter Ablation (Type: ACTIVE_COMPARATOR): Procedure/Surgery: Endocardial Catheter Ablation Treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete